Corbus Pharmaceuticals Holdings Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Corbus Pharmaceuticals Holdings, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.000.000.000.883.9436.144.82
Cost of Revenue0.6031.1716.1436.4598.270.000.00
Gross Profit-0.60-31.17-16.140.883.9436.140.00
Operating Expenses
Research & Development32.2231.1716.1436.4598.2789.6048.61
Selling, General & Administrative16.5013.9118.7020.4328.4823.6412.96
Operating Expenses48.1245.0818.7056.87126.75113.2561.57
Operating Income-48.72-45.08-34.84-55.99-122.81-77.10-56.75
Other Income/Expense
Interest Income6.311.640.960.880.100.000.98
Interest Expense1.873.86-3.10-2.71-1.130.000.00
Other Income/Expense8.512.700.0512.18-13.02-4.580.09
Income
Income Before Tax-40.21-44.60-42.35-45.64-111.27-71.45-55.67
Income Tax Expense0.000.000.000.000.000.000.00
Net Income-40.21-44.60-42.35-45.64-111.27-71.45-55.67
Net Income - Continuous Operations-40.21-44.60-42.35-45.640.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-37.74-40.11-34.07-54.35-121.12-71.45-56.25
EBIT-38.41-40.75-34.84-55.99-122.81-72.68-56.75
Depreciation & Amortization0.600.640.761.641.12-0.740.00
Earnings Per Share
Basic EPS-4.00-10.00-10.00-11.00-43.00--1.00
Diluted EPS-4.00-10.00-10.00-11.00-43.00-34.00-1.00
Basic Shares Outstanding10.924.334.174.102.602.1357.00
Diluted Shares Outstanding10.924.334.174.102.602.1357.00